Pulmonx (LUNG) Projected to Release Quarterly Earnings on Tuesday

Pulmonx (NASDAQ:LUNG) will likely be issuing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to post earnings of ($0.26) per share and revenue of $21.93 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The company had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. On average, analysts expect Pulmonx to post ($1.05) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Pulmonx Stock Performance

Shares of LUNG stock opened at $1.75 on Tuesday. The firm has a market cap of $75.16 million, a price-to-earnings ratio of -1.51 and a beta of 0.33. Pulmonx has a 52-week low of $1.13 and a 52-week high of $2.89. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95. The company’s 50 day moving average is $2.06 and its 200 day moving average is $1.65.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings raised Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Insider Activity at Pulmonx

In other Pulmonx news, insider Srikanth Radhakrishnan sold 14,245 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,193.70. Following the completion of the sale, the insider directly owned 316,994 shares in the company, valued at approximately $716,406.44. This trade represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Glendon French, III sold 41,882 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total value of $94,653.32. Following the completion of the sale, the chief executive officer owned 1,137,936 shares of the company’s stock, valued at approximately $2,571,735.36. This trade represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 78,340 shares of company stock valued at $177,048 in the last ninety days. Corporate insiders own 7.50% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a medical device company focused on developing and commercializing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its technologies are designed to improve lung function and quality of life by reducing the impact of damaged, overinflated portions of the lungs.

The company’s primary product is the Zephyr Endobronchial Valve, a small, one-way valve placed in the airways during a bronchoscopic procedure.